Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study

Zhou Tong¹, Lulu Liu¹, Yi Zheng¹, Weiqin Jiang¹, Peng Zhao¹,⁴, Weijia Fang¹,⁴ and Weilin Wang²,³,⁴*

Abstract

Background: Neutrophil-to-lymphocyte ratio (NLR) is one of the systemic inflammation markers, which has prognostic values in many types of tumor. However, hardly any research has reported the relationship between NLR and pancreatic neuroendocrine tumors (PanNETs). In this study, we aimed to evaluate the predictive value of the preoperative peripheral blood NLR on the clinical outcomes in patients of resectable PanNETs.

Methods: Ninety-five cases of PanNETs registered in the First Affiliated Hospital of Zhejiang University between March 2009 and May 2016 and underwent pancreatic surgery were included in this study. Univariate and multivariate analyses were applied to identify the prognostic factors for PanNETs. Prognostic nomogram and its calibration curve then used R (version 3.3.2) to predict lymph node (LN) metastasis.

Results: Among these 95 patients, 52 (54.7%) patients were diagnosed as grade 1 (G1) NET (mitotic count <2/10 HPF, Ki-67 ≤2%), 32 (33.7%) as G2 NET (mitotic count 2–20/10 HPF, Ki-67 3–20%), and 11 (11.6%) as G3 NEC (mitotic count >20/10 HPF, Ki-67 >20%). Increased NLR was found to relate with advanced T stage, LN metastasis, tumor thrombus formation, and advanced grade (p < 0.05 for all). Multivariate logistic regression was performed and indicated that NLR (HR 6.74; p = 0.02) was an independent prognostic factor for LN metastasis. Furthermore, we developed a nomogram based on the combination of NLR, T stage, and grade for LN metastasis with a good discrimination ability with the AUC (area under the curve) of 0.885. This nomogram showed larger AUC than those using NLR (0.725), T stage (0.808), or grade (0.708) alone as a prognostic factor, which means this system achieved a more optional performance in predicting clinical outcomes. Finally, the Kaplan–Meier curve indicated that the recurrence-free survival (RFS) of patients with high NLR (NLR >1.40, RFS 61.1 ± 4.4 months) decreased significantly as compared with those of low NLR (NLR ≤1.40, RFS 63.8 ± 2.9 months, p < 0.05).

Conclusions: The preoperative NLR is a potential independent predictor for LN metastasis and RFS. Our nomogram highlighted the important role of NLR in prognosis, which might be considered as a convenient indicator for lymph node metastasis, especially during the initial diagnosis for resectable PanNETs.

Keywords: Pancreatic neuroendocrine tumors, Neutrophil-to-lymphocyte ratio, Lymph node metastasis, Recurrence-free survival
Background
Pancreatic neuroendocrine tumors (PanNETs) are rare tumors with distinct clinical syndromes, which may obtain malignant potential [1, 2]. The worldwide incidence and prevalence of PanNETs increased recently, which may have resulted from the improved medical technology of detection [3, 4]. A minority of PanNETs are functional and accompanied with clinical syndrome of hormone excess such as insulin, gastrin, glucagon, somatostatin, or vasoactive intestinal peptide. Meanwhile, the majority of PanNETs are non-functional and asymptomatic as they do not secrete these active compounds. Due to this heterogeneous nature of PanNETs, identifying reliable prognostic features have been a challenge.

Recent studies have demonstrated that the survival and prognostic outcomes are associated with lymph node (LN) metastasis in PanNETs. Many studies showed survival benefits of patients without LN metastasis [5–11]. Moreover, awareness of LN status preoperatively may

Table 1 Patient characteristics

| Characteristics                        | Patients (cases (%)) |
|----------------------------------------|----------------------|
| Gender                                 |                      |
| Male                                   | 39 (41.1)            |
| Female                                 | 56 (58.9)            |
| Age, years                             | 54.4 ± 12.1          |
| TNM staging of ENETS in 2006           |                      |
| T1                                     | 34 (35.8)            |
| T2                                     | 28 (29.5)            |
| T3                                     | 21 (22.1)            |
| T4                                     | 12 (12.6)            |
| N0                                     | 80 (84.2)            |
| N1                                     | 15 (15.8)            |
| M0                                     | 80 (84.2)            |
| M1                                     | 15 (15.8)            |
| Grading classifications of WHO 2010    |                      |
| NET G1                                  | 52 (54.7)            |
| NET G2                                  | 32 (33.7)            |
| NEC G3                                  | 11 (11.6)            |
| Tumor thrombus                         |                      |
| Yes                                    | 6 (6.3)              |
| No                                     | 89 (93.7)            |
| Surgical resection                     |                      |
| Radical                                | 89 (93.7)            |
| Nonradical                             | 6 (6.3)              |
| Functioning tumor                      |                      |
| Yes                                    | 21 (22.1)            |
| No                                     | 74 (77.9)            |
| Blood loss volume, ml                  | 312.8 ± 661.2        |
| Operation duration, min                | 302.0 ± 158.0        |
| Surgical approaches                    |                      |
| Distal pancreatectomy                  | 47 (49.5)            |
| Local resection of pancreatic tumor    | 19 (20.0)            |
| Pancreatoduodenectomy                  | 27 (28.4)            |
| Total pancreatectomy                   | 2 (2.1)              |

Table 2 Preoperative NLR and clinical parameters

| Variables                           | Number | NLR (mean ± SD) | p    |
|-------------------------------------|--------|-----------------|------|
| Gender                              |        |                 |      |
| Male                                | 39     | 2.165 ± 0.980   | 0.908|
| Female                              | 56     | 2.134 ± 1.474   |      |
| Age                                 |        |                 |      |
| ≤60                                 | 60     | 2.102 ± 1.335   | 0.659|
| >60                                 | 35     | 2.224 ± 1.218   |      |
| TNM staging of ENETS in 2006        |        |                 |      |
| T1, T2                              | 62     | 1.909 ± 0.843   | 0.044|
| T3, T4                              | 33     | 2.594 ± 1.790   |      |
| N0                                  | 80     | 1.912 ± 0.836   | <0.001|
| N1                                  | 15     | 3.399 ± 2.282   |      |
| M0                                  | 80     | 2.094 ± 1.290   | 0.361|
| M1                                  | 15     | 2.427 ± 1.287   |      |
| New grading classifications of WHO in 2010 |  | | |
| NET G1                              | 52     | 1.862 ± 0.746   | 0.015|
| NET G2                              | 32     | 2.305 ± 1.597   |      |
| NEC G3                              | 11     | 3.031 ± 1.868   |      |
| Tumor thrombus                      |        |                 |      |
| Yes                                 | 6      | 3.703 ± 1.573   | 0.002|
| No                                  | 89     | 2.042 ± 1.207   |      |
| Functioning tumor                   |        |                 |      |
| Yes                                 | 21     | 2.049 ± 0.874   | 0.697|
| No                                  | 74     | 2.174 ± 1.387   |      |
| AFP                                 |        |                 |      |
| Normal                              | 91     | 2.171 ± 1.308   | 0.384|
| Abnormal                            | 4      | 1.594 ± 0.521   |      |
| CA199                               |        |                 |      |
| Normal                              | 93     | 2.163 ± 1.300   | 0.396|
| Abnormal                            | 2      | 1.378 ± 0.251   |      |
| CEA                                 |        |                 |      |
| Normal                              | 91     | 2.159 ± 1.312   | 0.665|
| Abnormal                            | 4      | 1.872 ± 0.444   |      |
| CA125                               |        |                 |      |
| Normal                              | 92     | 2.147 ± 1.300   | 0.979|
| Abnormal                            | 3      | 2.128 ± 1.067   |      |

NET neuroendocrine tumor, NEC neuroendocrine carcinoma, AFP alpha-fetoprotein, CA199 carbohydrate antigen 199, CEA carcinoembryonic antigen, CA125 carbohydrate antigen 125
improve preoperative risk stratification and therefore help to make a treatment decision, especially surgical options between the standard resection with LN harvest (pancreateico-duodenectomy and distal pancreatectomy) versus the parenchyma-sparing resection (enucleation and middle pancreatectomy) [9]. In combination with the two reasons stated above, earlier ascertainment of LN metastasis may attain clinical significance, providing more accurate and promising treatment strategies as early as the diagnosis, as well as obtaining prognostic information. Imaging techniques, as the most popular forms to detect LN metastasis traditionally, which include enhanced computed tomography (CT) and magnetic resonance imaging (MRI), can sometimes only offer limited information on LN metastasis. Their limitations include, but are not limited to, the inconsistent sensitivities and specificities, as well as patients’ potential allergy to the contrast and increased cost [12]. Therefore, proper and convenient predictive markers are needed to evaluate the risk of LN metastasis and survival of PanNETs at the initial time frame of the diagnosis.

The systemic inflammatory response (SIR), another critical factor to predict tumor invasion, metastasis and angiogenesis, has been demonstrated to be closely related with poor outcomes in most cancers over the past decades [6]. The white blood cell population changes such as increased neutrophils and deceased lymphocytes have been well recognized as signs of systemic inflammatory conditions [13, 14]. Because the neutrophil-to-lymphocyte ratio (NLR) can be easily measured, it has been thought as a marker of SIR and therefore intensively investigated in predicting prognostic outcomes and refining the risk stratification for cancer patients before treatment. Elevated NLR has been found to correlate with advanced stage and poor prognosis in many types of solid tumors, such as breast cancer, gastric cancer, pancreatic cancer, prostate cancer, and renal cancer [7, 15–24]. Even though, the association between NLR and the LN metastasis remains to be revealed in PanNETs. Here, we performed this retrospective study to evaluate the predictive value of the preoperative blood NLR on the LN metastatic status and, eventually, to provide evidence for prognosis of resectable PanNETs.

**Methods**

**Patients**

We retrospectively reviewed 95 cases of resectable PanNETs registered between March 2009 and May 2016 and underwent pancreatic surgery in the First Affiliated Hospital of Zhejiang University. The study followed the international and national regulations in accordance with the Declaration of Helsinki and was approved by the ethics committee of the First Affiliated Hospital, Zhejiang University. Patients’ characteristics were obtained including patient demographics, pathologic TNM staging, histology stage, tumor thrombus, functioning status, blood loss volume, operation duration, surgical approaches, and tumor markers. TNM staging was adopted according to the ENETS Consensus Guidelines [25]. Grade was adopted according to the new WHO 2010 grading classifications [26]. Peripheral blood samples for all 95 patients were collected right after the diagnosis before operation and any other therapeutic methods. We defined normal values of CEA (carcinoembryonic antigen), AFP (alpha-fetoprotein), CA199 (carbohydrate antigen 199), and CA125 (carbohydrate antigen 125) as 0–5 ng/ml, 0–20 ng/ml, 0–37 U/ml, and 0–35 U/ml, respectively.

**Postoperative follow-up**

Patients were followed by outpatient clinics or phone calls until September 2016. These follow-ups were achieved with 3-month intervals for the first 2 years and 6-month intervals for 2 to 5 years after operation. Recurrence-free survival (RFS) was defined as the number of months from the date of surgery to the date of
identification of disease recurrence (evaluated in outpatient clinics by radiological method: CT or MRI) or the date of last follow-up for progress-free patients. If the patient did not come to clinics at the predicted follow-up time, phone calls were made to ask if the patient had some clinical symptoms and to make sure of the survival status. In this study, the median follow-up duration was 31 (range 3–84) months.

Data analysis

All statistical analyses and graphics in this study were calculated and demonstrated by using the IBM SPSS Statistics software 20.0 and R software packages (version 3.3.2 URL http://www.r-project.org/). T tests were applied to compare variables with a normal distribution, whereas the Mann–Whitney U test was utilized to evaluate ranked variables. Univariate and multivariate logistic regression analyses were performed to analyze risk factors for LN metastasis. The Kaplan–Meier method was also adopted to calculate cumulative RFS, and comparisons between groups were achieved with the log-rank test. The ROC curve was used to estimate the performance of NLR to LN metastasis and RFS. On the basis of the results of the multivariable analysis, a nomogram was formulated by R software 3.2.0 with the rms package. The area under the curve (AUC) was used to assess the discrimination of the nomogram. The calibration plot with bootstrapping was adapted to illustrate the actual probability and the predicted probability [27]. Differences with two-sided p value <0.05 was considered statistically significant.

Results

Patient demographics

Of the 95 enrolled patients, there were 39 (41.1%) males and 56 (58.9%) females, with a mean age of 54.4 ± 12.1 years. There were 34, 28, 21, and 12 cases from stages T1 to T4, respectively. Fifteen patients were histologically confirmed to have LN metastasis. There were 52 patients defined as G1 NET (grade 1 neuroendocrine tumor; mitotic count 2/10 HPF, Ki-67 ≤2%), 32 as G2 NET (mitotic count 2–20/10 HPF, Ki-67 3–20%), 11 as G3 NEC (neuroendocrine carcinoma; mitotic count >20/10 HPF, Ki-67 >20%). Six patients were confirmed to have tumor thrombus by H&E stains of the resection specimen. Among the surgical choices for these patients, distal pancreatectomy was the most common surgical procedure (49.5%), followed by pancreaticoduodenectomy, local resection of pancreatic tumor, and total pancreatectomy (28.4, 20.0, and 2.1%, respectively). Radical resection was performed in 89 patients, while non-radical resection (not R0 resection, 6.3%) was performed for six patients. Of these 95 patients, 21 patients (22.1%) had functioning tumors. The operation duration ranged from 77.0 to 752.0 min, with an average of 302.0 ± 158.0 min. Average blood loss volume was 312.8 ± 661.2 ml (Table 1). Since there is no standard adjuvant therapeutic protocol for pancreatic neuroendocrine neoplasms, only eight patients received adjuvant therapy, including chemotherapy and somatostatin.

Table 3 Univariate and multivariate analyses of clinical characteristics according to lymph node metastasis

| Characteristics | Univariate | Multivariate |
|-----------------|------------|-------------|
|                 | HR (CI 95%) | p           | HR (CI 95%) | p           |
| Gender          |            |             |             |             |
| Male            | 2.5 (0.809, 7.722) | 0.111       |             |             |
| Female          | 1.0        |             | 1.0         |             |
| Age             |            |             |             |             |
| Age ≤60         | 0.833 (0.260, 2.672) | 0.759       | 0.979 (0.285, 3.487) | 0.931       |
| Age >60         | 1.0        |             | 1.0         |             |
| TNM staging of ENETS in 2006 |            |             |             |             |
| T1, T2          | 19.500 (4.047, 93.951) | <0.001      | 11.940 (2.098, 67.965) | 0.005       |
| T3, T4          |             |             |             |             |
| New grading classifications of WHO in 2010 |            |             |             |             |
| NET G1 + G2     | 16.625 (3.986, 69.349) | <0.001      | 10.378 (1.399, 77) | 0.022       |
| NEC G3          |             |             |             |             |
| Tumor thrombus  |            |             |             |             |
| Yes             | 14.182 (2.319, 86.74) | 0.004       | 0.603 (0.049, 7.429) | 0.693       |
| No              | 1.0        |             | 1.0         |             |
| AFP             |            |             |             |             |
| Normal          | 1.008 (0.993, 1.023) | 0.317       |             |             |
| Abnormal        |             |             |             |             |
| CA199           |            |             |             |             |
| Normal          | 0.989 (0.938, 1.043) | 0.684       |             |             |
| Abnormal        |             |             |             |             |
| CEA             |            |             |             |             |
| Normal          | 1.014 (0.687, 1.497) | 0.943       |             |             |
| Abnormal        |             |             |             |             |
| CA125           |            |             |             |             |
| Normal          | 1.033 (0.969, 1.102) | 0.320       |             |             |
| Abnormal        |             |             |             |             |
| NLR ≤2.056      | 7.429 (1.934, 28.540) | 0.003       | 6.740 (1.298, 34.998) | 0.023       |
| NLR >2.056      |             |             |             |             |
| Functional tumor|            |             |             |             |
| Yes             | 0.214 (0.026, 1.734) | 0.149       |             |             |
| No              |             |             |             |             |

NET neuroendocrine tumor, NEC neuroendocrine carcinoma, AFP alpha-fetoprotein; CA199 carbohydrate antigen 199, CEA carcinoembryonic antigen, CA125 carbohydrate antigen 125
analogs. The regimen of chemotherapy was etoposide plus
cisplatin or irinotecan.

Preoperative NLR and clinical parameters in PanNET patients
NEC G3 Patients had higher NLR as compared with NET
G2 and NET G1 patients \((p = 0.015)\). NLR in later T stage
(T3 and T4) patients also elevated as compared with
earlier T stage patients (T1 and T2) \((p = 0.044)\). In
addition, NLR elevated in tumor thrombus positive
\((p = 0.002)\) and LN metastasis \((p < 0.001)\) patients as well,
as shown in Table 2. As a contrast, the NLR was not
significantly associated with tumor markers including
AFP and CA125. In summary, higher NLR is related
with advanced tumor stage and higher grade.

Relationships between LN metastasis and NLR and other
clinicopathologic characteristics
ROC curve analysis was applied to categorize the opti-
mal cutoff values of NLR for LN metastasis, which
was settled as 2.056 (Fig. 1a). Based on this setting, we classi-
fied the patients into groups of “high NLR (>2.056)” and
“low NLR (≤2.056).” The sensitivity and specificity of the
cutoff for NLR were 80 and 65%, respectively. Univariate
analysis indicated that NLR (HR 7.429, \(p = 0.003\)), T
stage (HR 19.500, \(p < 0.001\)), status of tumor thrombus
(HR 14.182, \(p = 0.004\)), or histological grade (HR 16.625,
\(p < 0.001\)) showed significant differences between groups
with and without LN metastasis (Table 3). According
to the study described above, these four variables
were selected as potential independent risk factors in
multivariate analysis. Multivariate logistic regression
indicated that T stage (HR 11.940, \(p = 0.005\)) and grade (HR
10.378, \(p = 0.022\)), as well as NLR (HR 6.740, \(p = 0.023\)),
were all independent prognostic factors for LN metastasis.

Prognostic nomogram to predict LN metastasis
Furthermore, we developed a nomogram based on the
combination of these three independent factors to pre-
dict LN metastasis (Fig. 2). Specifically, ROC using the
combining system demonstrated a good discrimination
ability with the AUC of 0.885 (95% CI 0.783–0.987) (Fig. 3).
The under-the-curve area is larger than when using the individual factors
of NLR (0.725, 95% CI 0.591–0.859), T stage (0.808, 95% CI 0.693–0.924),
and grade (0.708, 95% CI 0.541–0.876). In addition, calibration plot with bootstrap
sampling \((n = 1000)\) summarized the performance cha-
racteristics of the nomogram (Fig. 4). Our bias-corrected
curve (solid line) was close to the ideal curve (dashed line).
This observation indicated that the nomogram was
well calibrated.

Comparison of RFS of high NLR with low NLR after
curative operation
The cutoff value revealed by ROC of NLR for RFS was
1.40 (Fig. 1b), and the Kaplan–Meier curve indicated
that the RFS of patients with high NLR (NLR >1.40, RFS
61.1 ± 4.4 months) decreased significantly as compared
with those of low NLR (NLR ≤1.40, RFS 63.8 ± 2.9 month, p < 0.05) (Fig. 5). The differences between the high and low NLR groups indicated NLR is a prognostic factor for resectable PanNETs.

**Discussion**

With an incidence of about 0.3 cases per 100,000 in the USA, PanNET is a type of rare neoplasm accounting for a minority of overall pancreatic tumors [4]. Although WHO and ENETS published authoritative staging and grading systems, prognostication of this disease still remains unclear [10]. Our study showed patients without LN metastasis had better RFS, and this result indicates the predictive value of LN status (Fig. 6). The observation that patients with LN metastasis had increased NLR encouraged us to explore the relationship between NLR and LN metastasis (Table 2).

More evidence confirmed that the systemic inflammatory response can increase the risk of cancer [13, 28–30]. Inflammatory responses participate in different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis [13]. Neutrophil is one of the dominant leukocyte subsets in peripheral blood and participates actively in promoting tumor genesis, progression, and metastasis. It can secrete various types of cytokines, including GM-CSF, TNF-α, IL-1, and IL-8 to boost tumor genesis.

---

**Fig. 4** Calibration plot of nomogram. The dashed line indicates the ideal nomogram in which predicted and actual probabilities were perfectly identical. The dotted line indicates actual nomogram performance. The solid line presents the bootstrap corrected performance of our nomogram. The calibration plot illustrates a good predictive accuracy.

**Fig. 5** Kaplan–Meier recurrence-free survival curves for the patients with PanNETs after resection. The survival curves show that the patients with high NLR decreased significantly as compared with those of low NLR.

**Fig. 6** Kaplan–Meier recurrence-free survival curves for the patients with PanNETs after resection. The survival curves show that the patients with LN positive decreased significantly as compared with those of LN negative.
and progression [31]. Circulating tumor-associated neutrophils can prolong tumor cell survival by suppressing the peripheral leukocyte activation [32]. Furthermore, neutrophil may facilitate tumor angiogenesis and metastasis by enhancing tumor cell adhesion to the endothelium [6, 33]. Tumor cells can be brought to the endothelium and adhere to lymphatic endothelium through interaction with neutrophils [17], and studies have noted that neutrophils can promote tumor cell adhesion to the microvascular wall by production of ROS [34]. In summary, neutrophils might serve as mediators of the LN metastasis.

Contrary to neutrophils, lymphocytes play an important role in cell-mediated immune response activation. Lymphocyte infiltration is common in NETs, as assessed by immunohistochemistry for CD3, CD4, CD8, and CD56 [35–37]. Tumor-infiltrating lymphocytes (TILs) have been shown to predict outcome in ovarian cancer, colorectal cancer, and hepatocellular carcinoma [38–40]. On the other hand, previous studies also indicated lymphopenia is associated with decreased survival [41, 42].

In combination with the effects of neutrophils and lymphocytes mentioned above, the NLR may be a potentially effective biomarker for tumor prognosis. Our data shows that NLR was an independent prognostic factor for LN metastasis and the RFS of patients with high NLR decreased significantly as compared with those of low NLR. Our conclusion concurs with other studies [17, 43]. In the meantime, our research also demonstrated that advanced T stage and grade were independent prognostic factors for LN metastasis, which is in accordance with previous studies, as well [9].

Nomogram, a new type of statistical prediction model, has been widely applied for cancer prognosis [44]. This model combines multiple relevant clinical predictors for readable and recognizable demonstrations. Because of these advantages, we established a nomogram model to evaluate the risk of LN metastasis of PanNETs by combining multiple factors of grade, T stage, and NLR. The new combined system demonstrated a good discrimination ability with an AUC of 0.885, higher than individual parameters. Moreover, the calibration plot illustrated a good predictive accuracy, which may predict a good concordance and a reliable ability to estimate the risk of LN metastasis. Our nomogram model is a simple graphical prediction tool that can be used for predicting the risk of LN metastasis of PanNETs. In this model, patients with high points are more likely to obtain LN metastasis. Therefore, this prediction system will provide more informational assistance for the surgeon to choose a more accurate and optimized surgical approach ahead. Also, patients with high NLR are more likely to be recurrent after operation, and as there is no standard adjuvant therapeutic protocol for pancreatic neuroendocrine neoplasms, NLR can be used as an assessment tool for doctors to apply adjuvant therapy.

Our study nevertheless had some limitations. Firstly, selection biases may be inevitable since our study was retrospective and hospital-based. Secondly, a multicenter study may be performed in the future to benefit the verification of our findings from this single-center analysis. Thirdly, due to the limited follow-up time, we were not able to demonstrate the significant difference between NLR and overall survival. Our future work will continue to follow up the patients’ status with prolonged observation time. Finally, the sample size is limited mostly due to the low incidence of PanNETs.

Conclusions

In conclusion, multivariate analysis demonstrated the role of preoperative NLR as a predictor for LN metastasis. Our nomogram model highlights the important role of NLR as a convenient and reliable indicator for LN metastasis, which may help physicians to evaluate the risk of LN metastasis before operation.

Abbreviations

AFP: Alpha-fetoprotein; AUC: Area under the curve; CA125: Carbohydrate antigen 125; CA199: Carbohydrate antigen 199; CEA: Carcinoembryonic antigen; LN: Lymph node; NEC: Neuroendocrine carcinoma; NET: Neuroendocrine tumor; NLR: Neutrophil-to-lymphocyte ratio; PanNETs: Pancreatic neuroendocrine tumors; RFS: Recurrence-free survival; SIR: Systemic inflammatory response

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (81472346, 81602128, 81572307), Natural Science Foundation of Zhejiang Province (LY15H160013), Zhejiang Key Subject of Clinical Medical Engineering (G3221), grants from the medical scientific project of Zhejiang Province (2013KYB087), the Major Program of Science and Technology of Zhejiang Province (2014C13G2010059), and grants from Zhejiang Medical Association (N20130053).

Availability of data and materials

Not applicable.

Authors’ contributions

WW and WF designed the research. ZT, YZ, and PZ drafted the manuscript of the research. WJ analyzed the data. LL critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
References

1. de Wilde RF, Edil BH, Hruban RH, Maitra A. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol. 2012;9:199–208.

2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469–92.

3. Rindi G, Wiedenmann B. Neuropoetendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8:54–64.

4. Yao JC, Hassan M, Phan A, Dagogo J, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthy JD, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3963–72.

5. Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE. Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience. J Gastrointest Surg. 2010;14:4891–8.

6. Kim JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat Inflamm. 2016;2016:4085147.

7. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vontolito S, Hbeshey A, Picon A, Bloom S. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30:432.

8. Tomasetti P, Campana D, Piscitelli V, Casadei R, Santini D, Nori F, Morselli-Labate AM, Pizzelli R, Corinaldesi R. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol. 2005;16:1806–10.

9. Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Labate AM, Pezzilli R, Corinaldesi R. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol. 2005;16:1806–10.

10. Lindberg JM, Walters DM, Stelow EB, Adams RB, Bauer TW. The incidence of non-functioning pancreatic neuroendocrine tumors <2 cm on preoperative imaging are increased in predicting/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30:432.

11. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.

12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.

13. He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia Y, Ohno Y, Namiki K, Chotai M, Tomoyue K, Tachibana M. Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol. 2016;23(Suppl 3):1048–54.

14. Hirahata N, Matsuura T, Mizota Y, Ishibashi S, Tajima Y. Prognostic value of preoperative inflammatory response biomarkers in patients with esophageal cancer who undergo a curative thoracoscopic esophagectomy. BMC Surg. 2016;16:66.

15. He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia Y, Ohno Y, Namiki K, Chotai M, Tomoyue K, Tachibana M. Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol. 2016;23(Suppl 3):1048–54.

16. Tsutsumetar A, Dursun M, Bexioglu H, Ozer K, Horasanli O, Ozbek E. Clinical significance of preoperative neutrophil - to - lymphocyte ratio in renal cell carcinoma. Int Braz J Urol. 2016;42:678–84.

17. Jiang K, Lei J, Chen W, Geng Y, Luo H, Li Z, Gong R, Zhu J. Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma. Medicine. 2016;95:e0579.

18. Gu X, Gao X, Li X, Qi X, Ma M, Qin S, Yu H, Sun S, Zhou D, Wang W. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep. 2016;6:22889.

19. Rindi G, Kloppel G, Couvelard A, Komminoth P, Komer M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpis A, Scacchi JY, Wiedenmann B. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Vrhchows Arch. 2007;451:757–62.

20. Bosman FT, Carneiro F, Hruban RH, Theise ND, Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. International Agency for Research on Cancer. 2010.

21. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.

22. Kazma R, Jefford MA, Cheng I, Plummer SJ, Levin AM, Rybicki BA, Casey G, Witte JS. Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS One. 2012;7:e51680.

23. Lund AW, Meder TR, Leachman SA, Coussens LM. Lymphatic vessels, inflammation, and immunity in skin cancer. Cancer Discov. 2016;6:22–35.

24. Wang H, Taverna D, Stram DQ, Fortini BK, Cheng I, Willkens LR, Burnett T, Makar KW, Lindor NW, Hopper JL, Gallinger S, Baron JA, Haile R, Kolel LN, Henderson BE, Newcomb PA, Casey G, Duggan D, Ulrich CM, Le Marchand L. Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2013;12:1004–10.

25. Millott SR, Paquin R, Menard C, Beaulieu AD. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med. 1992;176:593–8.

26. Zhang J, Qiao X, Shi H, Han X, Liu W, Tian X, Zeng X. Circulating tumor-associated neutrophils (CTAN) contribute to circulating tumor cell survival by suppressing peripheral leukocyte activation. Tumor Biol. 2016;37:597–604.

27. Liang W, Ferrara N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res. 2016;4:483–91.

28. Katz SC, Donkor C, Glasgow K, Pillarsetty VG, Gorin M, Espar N, Kimstra DS, D’Angelica MI, Allen PJ, Jamagin W, Dematteo RP, Brennan MF, Tang LH. T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumors and liver metastases. HPB (Oxford). 2012;14:764–83.

29. Vikman S, Giandomenico V, Sommaggio R, Oberg K, Essand M, Totterman TH. CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients. Cancer Immunol Immunother. 2008;57:399–409.

30. Papelis C, Jacobs B, Baran AM, Ehlers M, Stoecklein NH, Willenberg HS, Schinner S, Anlauf M, Raffel A, Cupisti K, Fenk R, Scherbaum WA, Schott M. Increased numbers of tumor-lysing monocytes in cancer patients. Mol Cell Endocrinol. 2011;337:52–61.
38. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.

39. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Ziadinahoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY). 2006;313:1960–4.

40. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13:902–11.

41. Wu ES, Oduyebo T, Cobb LP, Cholakian D, Kong X, Fader AN, Levinson KL, Tanner 3rd EJ, Stone RL, Piotrowski A, Grossman S, Long RK. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol. 2016;140:76–82.

42. Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzburg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urol Oncol. 2015;33:388.e19-25.

43. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23:200–7.

44. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70.